meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced - breast cancer (mBC) 1
cervical cancer (CC)
classical Hodgkin lymphoma (cHL)

immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone

versus all
vs immune chekpoint inhibitors
vs others immune checkpoint inhibitors
vs brentuximab vedotin

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -